Deciphering the Heterogeneity and Lineage Plasticity of Prostate Cancer Using High-Throughput Data: Broader, Finer and Objective

Published in Cancer and Protocols & Methods
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks
  1. Why this study is important

Nearly all early-stage prostate cancer cases are dependent on androgen receptor (AR) signaling, making AR-targeted therapy a cornerstone of prostate cancer management. Unlike other cancer types where resistance to targeted treatment is primarily due to mutations in the drug target, prostate cancer can evade targeted treatment through lineage-switching. In this process, prostate cancer cells bypass their dependency on AR signaling by acquiring alternative phenotypes, with the neuroendocrine (NE) phenotype being the most observed. Although rare, AR-/NE- phenotypes have also been reported. Additionally, prostate cancer cells with different phenotypes can be observed within a single tumor, and their composition varies during cancer progression and treatment resistance. There is an urgent need for molecular landscaping studies to describe the different prostate cancer phenotypes and develop novel therapeutic targets.

  1. How this research contributes to the field-directly

In our recently published paper, summarized in Figure 1, we performed a comprehensive and rigorous multi-omics study on prostate cancer samples from both humans and mice. We generated two prostate cancer single-cell datasets named HuPSA (human) and MoPSA (mouse) to describe cancer and stromal cell populations. Regarding cancer heterogeneity, we identified various AR+ prostate adenocarcinoma populations, neuroendocrine prostate cancer population, and, more importantly, two novel AR-/NE- populations named KRT7 and progenitor-like. We validated the existence of these novel populations using bulk RNAseq and immunohistochemistry. These identifications provided new diagnostic markers and laid the foundation for future mechanistic studies on these alternative phenotypes to develop new treatment strategies.

  1. How this research contributes to the field-indirectly

While drafting the manuscript, we realized that the comprehensive datasets generated for our research are also valuable to others. Our research analyzed only a handful of gene expressions, but the remaining data could be a hidden gem for other researchers who are insightful and smart but may lack bioinformatics skills. To facilitate this, we launched the HuPSA&MoPSA online website, where researchers can freely browse, visualize, and download the three datasets we generated. We hope that other researchers can identify even more interesting findings using our tool.

Besides the current website, we have developed other bioinformatics websites with different focuses, as summarized in Tabel 1 below:

Name

Purpose

URL

HuPSA&MoPSA

Single-cell prostate cancer transcriptome

https://pcatools.shinyapps.io/HuPSA-MoPSA/

ProAtlas

Bulk prostate cancer transcriptome

https://pcatools.shinyapps.io/HuPSA-MoPSA/

CTPC

Prostate cancer cell line transcriptome

https://pcatools.shinyapps.io/CTPC_V2/

PCTA

Pan-cancer cell line transcriptome

https://pcatools.shinyapps.io/PCTA_app/

LNCaP-ADT

LNCaP multi-omics

https://pcatools.shinyapps.io/shinyADT/

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Prostate Cancer
Life Sciences > Biological Sciences > Cancer Biology > Cancers > Urological Cancer > Prostate Cancer
Bioinformatics
Life Sciences > Biological Sciences > Biological Techniques > Computational and Systems Biology > Bioinformatics

Related Collections

With collections, you can get published faster and increase your visibility.

Noninvasive biomarkers: bridging real-world evidence and clinical trial data

This collection seeks to advance the discussion on noninvasive biomarkers by exploring their applications and implications across different data landscapes, namely real-world data (RWD) and clinical trial data.

Publishing Model: Open Access

Deadline: Sep 13, 2025

Cell-free DNA epigenomics for early cancer and MRD detection

This Collection invites cell-free DNA research focusing on early cancer and minimal residual disease detection that centers on epigenomic features (i.e. methylation, fragmentomics).

Publishing Model: Open Access

Deadline: Jul 14, 2025